文献速递细菌感染、耐药与抗菌药物

左氧氟沙星新型抗菌药levonadifloxacin对印度2016-18年临床分离株的体外活性:多中心监测研究

In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究为印度16家三级医院2016-18年ASPIRE监测的1376株临床分离株,采用参考琼脂稀释法和微量肉汤稀释法测定levonadifloxacin及对照药MIC。结果显示其对MSSA、MRSA及左氧氟沙星耐药金黄色葡萄球菌MIC50/90均为0.5/1或1/1 mg/L,对肺炎链球菌活性优于左氧氟沙星,对左氧氟沙星敏感肠杆菌目80.6%菌株在≤2 mg/L被抑制。

要点

  • levonadifloxacin对MSSA、MRSA及左氧氟沙星耐药金黄色葡萄球菌MIC50/90为0.5/1或1/1 mg/L。
  • 对肺炎链球菌MIC50/90为0.5/0.5 mg/L,优于左氧氟沙星(1/2 mg/L)。
  • 左氧氟沙星敏感肠杆菌目中80.6%菌株在≤2 mg/L levonadifloxacin被抑制。

核心结论

  • levonadifloxacin对当代MRSA和氟喹诺酮耐药葡萄球菌显示强效体外活性,为ABSSSI提供静脉及口服治疗选择。
  • 其对链球菌和左氧氟沙星敏感革兰阴性菌也有活性,呈现广谱活性特征。

研究设计与样本

  • 研究为印度多中心前瞻性监测(ASPIRE),纳入2016-18年12个邦16家三级医院的1376株临床分离株。
  • 分离株包括葡萄球菌677株、链球菌178株、肠杆菌目320株、铜绿假单胞菌140株、鲍曼不动杆菌61株。
  • 采用参考琼脂稀释法和微量肉汤稀释法测定levonadifloxacin及对照抗生素的MIC。

主要发现

  • 对MSSA、MRSA及左氧氟沙星耐药金黄色葡萄球菌,levonadifloxacin MIC50/90分别为0.5/1、0.5/1、1/1 mg/L。
  • 对凝固酶阴性葡萄球菌(含MDR株)MIC50/90为1/2 mg/L。
  • 对肺炎链球菌levonadifloxacin MIC50/90为0.5/0.5 mg/L,左氧氟沙星为1/2 mg/L。
  • 左氧氟沙星敏感肠杆菌目中80.6%菌株在≤2 mg/L levonadifloxacin被抑制。

关键数值与推荐

  • MSSA:levonadifloxacin MIC50/90 0.5/1 mg/L。
  • MRSA:levonadifloxacin MIC50/90 0.5/1 mg/L。
  • 左氧氟沙星耐药金黄色葡萄球菌:levonadifloxacin MIC50/90 1/1 mg/L。
  • 凝固酶阴性葡萄球菌(含MDR):levonadifloxacin MIC50/90 1/2 mg/L。
  • 肺炎链球菌:levonadifloxacin MIC50/90 0.5/0.5 mg/L,左氧氟沙星1/2 mg/L;左氧氟沙星敏感肠杆菌目80.6%在≤2 mg/L被抑制。

临床怎么用

  • 对于ABSSSI(包括糖尿病足感染)中MRSA或氟喹诺酮耐药金黄色葡萄球菌,levonadifloxacin可作为静脉或口服治疗选项。
  • 对肺炎链球菌感染,levonadifloxacin体外活性优于左氧氟沙星。
  • 对左氧氟沙星敏感肠杆菌目感染,levonadifloxacin可能覆盖约80.6%菌株(≤2 mg/L),但需结合临床。

局限性

  • 研究为体外药敏监测,未提供临床疗效与安全性数据。
  • 仅纳入印度16家医院2016-18年分离株,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Levonadifloxacin is a novel antibiotic belonging to the benzoquinolizine subclass of fluoroquinolones with potent activity against MRSA and quinolone-resistant Staphylococcus aureus. IV levonadifloxacin and its oral prodrug alalevonadifloxacin have recently been approved in India for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) including diabetic foot infections. OBJECTIVES: To investigate the in vitro activity of levonadifloxacin against contemporary clinical isolates collected from multiple tertiary care hospitals across India in the Antimicrobial Susceptibility Profiling of Indian Resistotypes (ASPIRE) surveillance study. METHODS: A total of 1376 clinical isolates, consisting of staphylococci (n = 677), streptococci (n = 178), Enterobacterales (n = 320), Pseudomonas aeruginosa (n = 140) and Acinetobacter baumannii (n = 61), collected (2016-18) from 16 tertiary hospitals located across 12 states in India, were included in the study. The MICs of levonadifloxacin and comparator antibiotics were determined using the reference agar dilution method and broth microdilution method. RESULTS: Levonadifloxacin exhibited potent activity against MSSA (MIC50/90: 0.5/1 mg/L), MRSA (MIC50/90: 0.5/1 mg/L) and levofloxacin-resistant S. aureus (MIC50/90: 1/1 mg/L) isolates. Similarly, potent activity of levonadifloxacin was also observed against CoNS including MDR isolates (MIC50/90: 1/2 mg/L). Against Streptococcus pneumoniae, levonadifloxacin (MIC50/90: 0.5/0.5 mg/L) showed superior activity compared with levofloxacin (MIC50/90: 1/2 mg/L). Among levofloxacin-susceptible Enterobacterales, 80.6% of isolates were inhibited at ≤2 mg/L levonadifloxacin. CONCLUSIONS: Levonadifloxacin displayed potent activity against contemporary MRSA and fluoroquinolone-resistant staphylococcal isolates, thus offering a valuable IV as well as an oral therapeutic option for the treatment of ABSSSIs. Furthermore, levonadifloxacin exhibited a broad-spectrum activity profile as evident from its activity against streptococci and levofloxacin-susceptible Gram-negative isolates.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Appalaraju B, Baveja S, Baliga S, et al. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18. J Antimicrob Chemother. 2020. PMID: 31840170. doi:10.1093/jac/dkz493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。